Epiford 200mg Tablet CR contains Sodium Valproate, an anticonvulsant and mood-stabilizing agent primarily used in the management of epilepsy, bipolar disorder, and prevention of migraine headaches. Each controlled-release tablet delivers 200mg of Sodium Valproate, ensuring a sustained therapeutic effect with reduced dosing frequency. Sodium Valproate acts by increasing gamma-aminobutyric acid (GABA) levels in the brain, thereby stabilizing neuronal activity and preventing seizure propagation. Epiford 200mg Tablet CR is indicated for the treatment of various seizure types, including absence seizures, complex partial seizures, and generalized tonic-clonic seizures. Additionally, it is utilized as a mood stabilizer in bipolar disorder to reduce manic episodes and as prophylaxis for migraine attacks. The controlled-release formulation enhances patient compliance by maintaining steady plasma drug concentrations, minimizing peak-related side effects. Common adverse effects may include gastrointestinal disturbances, dizziness, weight gain, and tremors; serious but rare effects include hepatotoxicity and pancreatitis, necessitating regular monitoring of liver function and blood counts. Epiford 200mg Tablet CR should be prescribed with caution in patients with hepatic impairment, mitochondrial disorders, or a history of pancreatitis. It is contraindicated during pregnancy unless benefits outweigh risks, due to teratogenic potential. Dose adjustments may be required based on clinical response and tolerability.